SCHEMBL5666262

SCHEMBL5666262

CC(C)(C)c1cc(I)cc(I)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.46
GABRB2 P47870 1/20 0.46
POLB P06746 1/20 0.42
HMGCR P04035 1/20 0.41
GAA P10253 2/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TTR P02766 1/20 0.36
HTR1D P28221 2/20 0.36
TSHR P16473 1/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
LMNA P02545 1/20 0.33
TYR P14679 1/20 0.33
APP P05067 1/20 0.33
CYP2C19 P33261 1/20 0.33
HTR1B P28222 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9922034 0.94 GABRA1 (0.52) GABRA1GABRB2POLBHMGCRGAA
SCHEMBL30138691 0.84 POLB (0.41) GABRA1GABRB2POLBHMGCRGAA
SCHEMBL3196711 0.84 POLB (0.41) GABRA1GABRB2POLBHMGCRGAA
SCHEMBL18077869 0.82 GABRA1 (0.48) GABRA1GABRB2POLBHMGCRGAA
SCHEMBL21327977 0.82 POLB (0.44) GABRA1GABRB2POLBHMGCRGAA
SCHEMBL18077868 0.82 GABRA1 (0.42) GABRA1GABRB2POLBHMGCRGAA
SCHEMBL21986188 0.82 GABRA1 (0.37) GABRA1GABRB2POLBHMGCRGAA
SCHEMBL21118089 0.82 GABRA1 (0.37) GABRA1GABRB2POLBHMGCRGAA
SCHEMBL18077879 0.82 GABRB2 (0.42) GABRA1GABRB2POLBHMGCRGAA
SCHEMBL16956188 0.82 GABRA1 (0.37) GABRA1GABRB2POLBHMGCRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11053228-B2 Condensed cyclic compound, composition including the condensed cyclic compound, and organic light-emitting device including the condensed cyclic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2021-07-06 US disclosed
US-11000038-B2 Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients MITSUI CHEMICALS AGRO, INC. (JP) 2021-05-11 US disclosed
US-20200196600-A1 PYRIDONE COMPOUNDS AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS MITSUI CHEMICALS AGRO, INC. (JP) 2020-06-25 US disclosed
US-20200031812-A1 CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND SAMSUNG SDI CO., LTD. (KR) 2020-01-30 US disclosed
US-8716226-B2 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists SAINT LOUIS UNIVERSITY (US) 2014-05-06 US disclosed
US-8716226-B2 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists SAINT LOUIS UNIVERSITY (US) 2014-05-06 US disclosed
US-20140051715-A1 3,5 Phenyl-Substituted Beta Amino Acid Derivatives as Integrin Antagonists SAINT LOUIS UNIVERSITY (US) 2014-02-20 US disclosed
US-20140051715-A1 3,5 Phenyl-Substituted Beta Amino Acid Derivatives as Integrin Antagonists SAINT LOUIS UNIVERSITY (US) 2014-02-20 US disclosed
EP-1734942-A1 SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2006-12-27 EP disclosed
EP-1729755-A1 METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2006-12-13 EP disclosed
US-20060014790-A1 Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors ELAN PHARMACEUTICALS, INC. 2006-01-19 US disclosed
US-20050261273-A1 Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors ELAN PHARMACEUTICALS, INC. 2005-11-24 US disclosed
WO-2005087215-A1 SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2005-09-22 WO disclosed
WO-2005087215-A1 SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2005-09-22 WO disclosed
WO-2005070407-A1 METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2005-08-04 WO disclosed
WO-2005070407-A1 METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2005-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261273-A1 Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors DNPEP, ASPH, PEPD GABRA1 3119/4885GABRB2 3080/4885POLB 1917/4885
US-20140051715-A1 3,5 Phenyl-Substituted Beta Amino Acid Derivatives as Integrin Antagonists ITGB3, ITGB5, ITGA5 GABRA1 129/4885GABRB2 181/4885POLB 2648/4885
US-11053228-B2 Condensed cyclic compound, composition including the condensed cyclic compound, and organic light-emitting device including the condensed cyclic compound CCNL2, ARL1, CRY1 GABRA1 3865/4885GABRB2 4384/4885POLB 1668/4885
US-20200196600-A1 PYRIDONE COMPOUNDS AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS PNPO, PDXK, PLPBP GABRA1 1944/4885GABRB2 2725/4885POLB 3861/4885
US-20200031812-A1 CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND CCNL2, ARL1, CRY1 GABRA1 3865/4885GABRB2 4384/4885POLB 1668/4885
US-20060014790-A1 Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors ASPH, DNPEP, ACE GABRA1 4222/4885GABRB2 3994/4885POLB 2121/4885
US-11000038-B2 Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients PNPO, PDXK, PLPBP GABRA1 1944/4885GABRB2 2725/4885POLB 3861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.